Replies to post #219844 on Biotech Values

[vlad33301]

AKBA KERX - Baupost owns 39.66% of KERX shares, and after coversion of notes that percentage will be even greater. I don't see why this would not go through.

https://www.streetinsider.com/SEC+Filings/Form+SC+13DA+KERYX+BIOPHARMACEUTICALS+Filed+by%3A+BAUPOST+GROUP+LLCMA/14176735.html

[DewDiligence]

AKBA -13%—presumably from this in 2Q18 PR:

https://finance.yahoo.com/news/akebia-therapeutics-announces-second-quarter-200500144.html

Completed U.S. enrollment of the Phase 3 INNO2VATE Conversion study, targeting full enrollment of the INNO2VATE program globally by the end of 2018. The company expects top-line results for the program in the fourth quarter of 2019 or the first quarter of 2020, subject to the accrual of major adverse cardiac events (MACE);